FINWIRES · TerminalLIVE
FINWIRES

美国股市指数延续伊朗停火协议带来的涨幅,停火协议或将维持至巴基斯坦谈判结束。

-- 周四,美国股指上涨,而原油期货涨幅收窄,市场预期巴基斯坦斡旋达成的伊朗停火协议将持续有效,直至在伊斯兰堡举行进一步谈判以结束战争。 纳斯达克综合指数上涨0.8%,收于22,822.42点;标普500指数上涨0.6%,收于6,824.66点;道琼斯工业平均指数上涨0.6%,收于48,185.80点,延续了周三的强劲涨势。 英国独立电视台(ITV)报道称,伊朗副外长赛义德·哈提卜扎德表示,霍尔木兹海峡已开放。哈提卜扎德告诉ITV,任何民用船只在伊朗当局的指导下均可通过。“任何与伊朗当局沟通的人都可获准通过。” 《华尔街日报》报道称,周四共有8艘船只通过霍尔木兹海峡,低于通常的每日135艘。 据美国有线电视新闻网(CNN)报道,为期两周的停火协议似乎仍在维持,周四中东地区发生的袭击事件有所减少。路透社报道称,以色列周三对黎巴嫩的袭击造成超过250人死亡,数百人受伤。 此外,内塔尼亚胡提出的与黎巴嫩进行谈判以解除据称是伊朗代理人武装的黎巴嫩武装组织的计划,回应了伊朗总统马苏德·佩泽什基安提出的担忧。路透社援引佩泽什基安的话说,特拉维夫对黎巴嫩的袭击违反了停火协议,更重要的是,这将使即将在伊斯兰堡举行的美伊和平谈判失去意义。 据CNN报道,内塔尼亚胡表示,以色列正计划与黎巴嫩进行直接谈判以建立和平关系,但他补充说,在谈判进行期间不会停火。 据媒体报道,美国副总统约翰·万斯将于周六率领美国谈判代表在伊斯兰堡与伊朗举行会谈。据报道,特朗普告诉NBC新闻,他对与伊朗达成和平协议“非常乐观”,但警告说,“如果他们不达成协议,后果将非常严重。” 西德克萨斯中质原油期货上涨4.7%,至每桶98.88美元,此前盘中一度飙升超过7%。布伦特原油期货上涨2.4%,至每桶97.01美元,盘中一度上涨近5%。 大多数美国国债收益率下跌,两年期国债收益率下降1.5个基点至3.78%。十年期国债收益率基本持平,为4.28%。 经济方面,个人消费支出价格指数上涨0.4%,同比涨幅如预期维持在2.8%。该价格指数1月份环比上涨0.3%。 核心个人消费支出(PCE)价格指数上涨0.4%,与预期一致,与1月份持平。同比增速从上月的3.1%降至3%。 美国第四季度经济增长率(以国内生产总值衡量)从第二次预估值的0.7%下调至0.5%,而彭博社调查的预期为维持不变。 截至4月4日当周,美国首次申请失业救济人数升至21.9万人,高于前一周向上修正后的20.3万人,而彭博社调查的预期为21万人。 贵金属方面,黄金期货上涨0.4%至每盎司4794.4美元,白银期货上涨0.5%至每盎司75.79美元。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA